Skip to main content

Advertisement

Fig. 3 | Journal of Translational Medicine

Fig. 3

From: 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling

Fig. 3

Boxplot representation of the gene expression levels (logarithm base 2 normalized intensity) before (B) and 24h after initiation of bevacizumab/erlotinib in the KEGG pathways “Hematopoietic cell lineage” (hsa04640), “ABC transporters” (hsa02010), and “Pathways in cancer” (hsa05200). The genes depicted in this representation belong the list of the 100 most dysregulated genes

Back to article page